Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder-To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial

被引:58
作者
Abdel-Meguid, Taha A. [1 ,2 ]
机构
[1] King Abdulaziz Univ Med City, Dept Urol, Jeddah, Saudi Arabia
[2] Menia Univ, Dept Urol, El Minia, Egypt
关键词
urinary bladder; neurogenic; spinal cord injuries; botulinum toxin type A; urinary incontinence; urodynamics; IDIOPATHIC DETRUSOR OVERACTIVITY; INTRADETRUSOR INJECTIONS; INCONTINENCE; STANDARDIZATION; TERMINOLOGY;
D O I
10.1016/j.juro.2010.08.028
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The short-term outcomes of initial detrusor injections vs combined detrusor-trigone botulinum toxin-A injections were determined in patients with spinal cord injury-neurogenic detrusor overactivity. Materials and Methods: Adults with refractory spinal cord injury-neurogenic detrusor overactivity who strictly discontinued anticholinergics were recruited for the study. At a 1: 1 ratio patients randomly received 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm) or 200 U intradetrusor plus 100 U intratrigonal injections (combined arm). Study end points were determination of the impact on incontinence episodes, complete dryness, quality of life, reusing anticholinergics, maximum detrusor pressure, reflex volume, maximum cystometric capacity, vesicoureteral reflux and adverse events. Patients were evaluated at baseline, and 2, 8, 12 and 18 weeks after injection. Statistical significance was considered at p<0.05. Results: Analysis included 18 patients per arm with no significant baseline differences. On within group analysis all parameters improved significantly compared to baseline. On between group analysis in the detrusor vs the combined arm at week 8 incontinence decreased by 52.4% vs 80.9% (number needed to treat 1.91 vs 1.23 patients, p<0.001), complete dryness was achieved in 33.3% vs 66.7% of patients (number needed to treat 3 vs 1.5, p<0.001) and quality of life score was decreased by 46.76% vs 48.13% (number needed to treat 2.14 vs 2.08, p<0.44). The absolute difference was 60% vs 82.5% for reflex volume (p<0.001), 66.2% vs 68.4% for maximum cystometric capacity (p<0.22) and -42.3% vs -41.9% for maximum detrusor pressure (p<0.21). At week 18 anticholinergics were needed again in 9 (50%) and 4 patients (22.2%) patients, respectively. No patient showed new or upgraded vesicoureteral reflux or reported significant adverse events. Conclusions: In the short term all parameters improved significantly in each arm. The superiority of including rather than excluding the trigone was significant.
引用
收藏
页码:2423 / 2428
页数:6
相关论文
共 21 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]   Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity [J].
Apostolidis, A ;
Dasgupta, P ;
Fowler, CJ .
EUROPEAN UROLOGY, 2006, 49 (04) :644-650
[3]   Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type a for the treatment of neurogenic or idiopathic detrusor overactivity [J].
Apostolidis, Apostolos ;
Jacques, Thomas S. ;
Freeman, Alex ;
Kalsi, Vinay ;
Popat, Roshni ;
Gonzales, Gwendoline ;
Datta, Soumendra N. ;
Ghazi-Noori, Shabnam ;
Elneil, Sohier ;
Dasqupta, Prokar ;
Fowler, Clare J. .
EUROPEAN UROLOGY, 2008, 53 (06) :1245-1253
[4]   Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report [J].
Apostolidis, Apostolos ;
Dasgupta, Prokar ;
Denys, Pierre ;
Elneil, Sohier ;
Fowler, Clare J. ;
Giannantoni, Antonella ;
Karsenty, Gilles ;
Schulte-Baukloh, Heinrich ;
Schurch, Brigitte ;
Wyndaele, Jean-Jacques .
EUROPEAN UROLOGY, 2009, 55 (01) :100-120
[5]   Botulinum toxin - New mechanisms, new therapeutic directions? [J].
Chapple, C ;
Patel, A .
EUROPEAN UROLOGY, 2006, 49 (04) :606-608
[6]   Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat [J].
Chuang, Yao-Chi ;
Yoshimura, Naoki ;
Huang, Chao-Cheng ;
Wu, Moya ;
Chiang, Po-Hui ;
Chancellor, Michael B. .
JOURNAL OF UROLOGY, 2008, 180 (02) :742-748
[7]   Six-Year Follow-Up of Botulinum Toxin A Intradetrusorial Injections in Patients with Refractory Neurogenic Detrusor Overactivity: Clinical and Urodynamic Results [J].
Giannantoni, Antonella ;
Mearini, Ettore ;
Del Zingaro, Michele ;
Porena, Massimo .
EUROPEAN UROLOGY, 2009, 55 (03) :705-712
[8]   Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder:: A systematic literature review [J].
Karsenty, Gilles ;
Denys, Pierre ;
Amarenco, Gerard ;
De Seze, Marianne ;
Game, Xavier ;
Haab, Francois ;
Kerdraon, Jacques ;
Perrouin-Verbe, Brigitte ;
Ruffion, Alain ;
Saussine, Christian ;
Soler, Jean-Marc ;
Schurch, Brigitte ;
Chartier-Kastler, Emmanuel .
EUROPEAN UROLOGY, 2008, 53 (02) :275-287
[9]   Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux [J].
Karsenty, Gilles ;
Elzayat, Ehab ;
Delapparent, Thomas ;
St-Denis, Benoit ;
Lemieux, Marie-Claude ;
Corcos, Jacques .
JOURNAL OF UROLOGY, 2007, 177 (03) :1011-1014
[10]   Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity [J].
Karsenty, Gilles ;
Reitz, Andre ;
Lindemann, Gertraud ;
Boy, Sonke ;
Schurch, Brigitte .
UROLOGY, 2006, 68 (06) :1193-1197